China Medical University Hospital

cmuh.org.tw

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

465

Active

85

Phase 3

13

Total enrollment

819,518

Pipeline matrix

Showing 26 of 26 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Dexamethasone and N-acetylcysteine1
NMDAE7
NMDAE plus Placebo Cap3
NMDAE plus AIFA2
Alectinib2
ADSC011
B10 L-BPA1
Drug: B10 L-BPA1
S1RA plus NMDAE1
S1RA plus Placebo Cap1
S-11
Nintedanib, gefitinib, erlotinib, afatinib, osimertinib1
NMDAE plus AO1
Sertraline1
Imatinib1
Trametinib1
Nivolumab2
all trans retinoic acid1
Methylene Blue1
Omega-3 fatty acids1
Traditional Chinese Medicine treatment1
Pembrolizumab1
Blood Biomarker Sampling1
steroid therapy1
0.01% concentration atropine drops1
0.025% atropine eye drops1

Next readouts

  • 2025-02-28
  • 2026-05-20
  • 2026-05-31
  • 2026-06
  • 2026-08-27
  • 2026-08-31
  • 2026-10
  • 2026-10-30
  • 2026-11
  • 2026-11

Top conditions

  • Stroke11
  • Schizophrenia11
  • Breast Cancer9
  • Healthy8
  • Acupuncture8
  • Knee Osteoarthritis7
  • Major Depressive Disorder6
  • Ischemic Stroke6

Frequently asked questions about China Medical University Hospital

How many clinical trials does China Medical University Hospital have on ClinicalTrials.gov?
China Medical University Hospital is listed as the lead sponsor on 465 clinical trials in ClinicalTrials.gov, 85 of which are currently active (recruiting, enrolling, or ongoing).
How many of China Medical University Hospital's trials are in Phase 3?
13 of China Medical University Hospital's trials are in Phase 3, spread across 26 active drug programs.
What therapeutic areas does China Medical University Hospital focus on?
China Medical University Hospital's most-studied conditions on ClinicalTrials.gov are Stroke, Schizophrenia, Breast Cancer, Healthy, Acupuncture.
When are China Medical University Hospital's next clinical trial readouts?
China Medical University Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer”, expected around 2025-02-28.